$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

$ctxr Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000121390024113149 Filed on December 27, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$2.127M		$11.91M
YoY Change	-18.87%		-19.66%
% of Gross Profit
Depreciation & Amortization	$0.00		$1.432K
YoY Change	-100.0%		-46.33%
% of Gross Profit
Operating Expenses	$10.04M		$42.00M
YoY Change	7.48%		14.33%
Operating Profit	-$10.04M		-$42.00M
YoY Change	7.48%		14.33%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$22.61K		$3.146M
YoY Change	-91.09%		-33.98%
Pretax Income	-$10.02M		-$38.85M
YoY Change	10.23%		21.53%
Income Tax	$264.2K		$576.0K
% Of Pretax Income
Net Earnings	-$10.28M		-$39.43M
YoY Change	11.38%		21.15%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.30		-$5.97
Diluted Earnings Per Share	-$1.30		-$5.97
COMMON SHARES
Basic Shares Outstanding	7.727M shares	180.7M shares	6.727M shares
Diluted Shares Outstanding	7.492M shares		6.727M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$1.100M	$3.252M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$14.38M	$8.269M
Prepaid Expenses	$2.846M	$2.700M
Receivables
Other Receivables
Total Short-Term Assets	$18.33M	$14.22M
YoY Change	-35.03%	-58.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill	$9.347M	$9.347M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$102.2M	$102.2M
YoY Change	268383.6%	268383.6%
Total Long-Term Assets	$102.4M	$102.4M
YoY Change	47.96%	47.93%
TOTAL ASSETS
Total Short-Term Assets	$18.33M	$14.22M
Total Long-Term Assets	$102.4M	$102.4M
Total Assets	$120.7M	$116.7M
YoY Change	23.93%	12.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.364M	$4.927M
YoY Change	178.18%	68.32%
Accrued Expenses	$6.242M	$17.03K
YoY Change	2154.33%	-96.43%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.81M	$35.81M
YoY Change	703.14%	519.74%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.81M	$35.81M
Total Long-Term Liabilities
Total Liabilities	$51.78M	$42.55M
YoY Change	329.2%	249.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$211.1M	-$201.4M
YoY Change	23.14%	24.13%
Common Stock	$7.727K	$7.247K
YoY Change	-95.14%	-95.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$65.41M	$70.08M
YoY Change
Total Liabilities & Shareholders Equity	$120.7M	$116.7M
YoY Change	23.93%	12.59%

Cashflow Statement

Concept	2024 Q4	2024
OPERATING ACTIVITIES
Net Income	-$10.28M	-$39.43M
YoY Change	11.38%	21.15%
Depreciation, Depletion And Amortization	$0.00	$1.432K
YoY Change	-100.0%	-46.33%
Cash From Operating Activities	-$4.726M	-$28.20M
YoY Change	-22.97%	-2.96%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$5.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$252.1K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.574M	$9.972M
YoY Change		-27.89%
NET CHANGE
Cash From Operating Activities	-$4.726M	-$28.20M
Cash From Investing Activities		-$5.000M
Cash From Financing Activities	$2.574M	$9.972M
Net Change In Cash	-$2.152M	-$23.23M
YoY Change	-64.93%	52.51%
FREE CASH FLOW
Cash From Operating Activities	-$4.726M	-$28.20M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024	us-gaap	Revenues Revenues		usd
CY2023	us-gaap	Revenues Revenues		usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-38174
CY2024	dei	Entity Registrant Name EntityRegistrantName	Citius Pharmaceuticals, Inc.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3425913
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Commerce Drive
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	First Floor
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranford
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07016
CY2024	dei	City Area Code CityAreaCode	(908)
CY2024	dei	Local Phone Number LocalPhoneNumber	967-6677
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024	dei	Trading Symbol TradingSymbol	CTXR
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	131670000000000	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7727243	shares
CY2024	cyd	Cybersecurity Risk Third Party Oversight And Identification Processes Flag CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag	true
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag	true
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Report To Board Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	dei	Auditor Firm AuditorFirmId	392
CY2024	dei	Auditor Name AuditorName	Wolf & Company, P.C.
CY2024	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3251880	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26480928	usd
CY2024Q3	us-gaap	Inventory Gross InventoryGross	8268766	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2700000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7889506	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	14220646	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	34370434	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1432	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246247	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	454426	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38062	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38062	usd
CY2024Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	92800000	usd
CY2023Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2023Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	102184858	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	68784858	usd
CY2024Q3	us-gaap	Assets Assets	116651751	usd
CY2023Q3	us-gaap	Assets Assets	103611150	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4927211	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2927334	usd
CY2024Q3	ctxr	License Payable LicensePayable	28400000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17027	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	476300	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2229018	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2156983	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	241547	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	218380	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	35814803	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5778997	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6713800	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6137800	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21318	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262865	usd
CY2024Q3	us-gaap	Liabilities Liabilities	42549921	usd
CY2023Q3	us-gaap	Liabilities Liabilities	12179662	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7247243	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7247243	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6354371	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6354371	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	7247	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	6354	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	271440421	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	253056133	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201370218	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162231379	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	70077450	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	90831108	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	4024380	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74101830	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91431488	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116651751	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103611150	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11906601	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14819729	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18249402	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15295584	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	11839678	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6616705	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	41995681	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	36732018	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-41995681	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-36732018	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	758000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1179417	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2387842	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3585689	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3145842	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4765106	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38849839	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31966912	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	576000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	576000	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-39425839	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32542912	usd
CY2024	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-287000	usd
CY2024	ctxr	Deemed Dividend On Warrant Extension DeemedDividendOnWarrantExtension	1047312	usd
CY2023	ctxr	Deemed Dividend On Warrant Extension DeemedDividendOnWarrantExtension	1151208	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40186151	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33694120	usd
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.97
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.97
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.57
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.57
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6726999	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6726999	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6051789	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6051789	shares
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	102000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31267	usd
CY2023	ctxr	Direct Offering Net Of Costs DirectOfferingNetOfCosts	1201818	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13798183	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6616705	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32542912	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91431488	usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	284176	usd
CY2024	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	13803684	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11839678	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2358780	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3831357	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-39425839	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74101830	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-39425839	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32542912	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	11839678	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6616705	usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	284176	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	102000	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	208179	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	191648	usd
CY2024	us-gaap	Depreciation Depreciation	1432	usd
CY2023	us-gaap	Depreciation Depreciation	2668	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	576000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	576000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2133871	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	945389	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5036926	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1999877	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1761956	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-459273	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-929094	usd
CY2024	ctxr	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	72035	usd
CY2023	ctxr	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	394732	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-218380	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-196989	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28201375	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29060212	usd
CY2024	ctxr	License Payment LicensePayment	5000000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31267	usd
CY2024	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	3831357	usd
CY2024	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13803684	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13798183	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9972327	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13829450	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-23229048	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-15230762	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26480928	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41711690	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3251880	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26480928	usd
CY2024	ctxr	Ip Ramp D Milestones Included In License Payable IPRampDMilestonesIncludedInLicensePayable	28400000	usd
CY2024	ctxr	Prepaid Manufacturing Transferred To Inventory PrepaidManufacturingTransferredToInventory	6134895	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharmaceuticals, Inc. (“Citius Pharma,” the “Company” or “we”) is a late-stage biopharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products and stem cell therapies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 30, 2016, we acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary. We acquired all the outstanding stock of LMB by issuing shares of our common stock. The net assets acquired included identifiable intangible assets of $19,400,000 related to in-process research and development. We recorded goodwill of $9,346,796 for the excess of the purchase price over the net assets acquired.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 11, 2020, we formed NoveCite, Inc. (“NoveCite”), a Delaware corporation, of which we own 75% of the issued and outstanding capital stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 23, 2021, we formed Citius Oncology, Inc. (formerly named Citius Acquisition Corp.) (“Citius Oncology”), as a wholly-owned subsidiary in conjunction with the acquisition of LYMPHIR, which began operations in April 2022. On August 12, 2024, Citius Pharma and Citius Oncology entered into a merger agreement with TenX Keane Acquisition, and its wholly owned subsidiary, TenX Merger Sub Inc (“Merger Sub”), whereby Merger Sub merged with and into Citius Oncology. After the merger and recapitalization (the “Merger”), the newly combined publicly traded company is owned 92.3% by Citius Pharma, and is named Citius Oncology, Inc. (see Note 9).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since its inception, we have devoted substantially all our efforts to business planning, research and development, recruiting management and technical staff, and raising capital. We are subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by the Company or its competitors of research and development stage products, regulatory approval and market acceptance of its products, competition from larger companies, dependence on key personnel, dependence on key suppliers and strategic partners, the Company’s ability to obtain additional financing and the Company’s compliance with governmental and other regulations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the operations of Citius Pharmaceuticals, Inc., and its wholly-owned subsidiaries, Citius Pharmaceuticals, LLC and LMB and its majority-owned subsidiaries NoveCite and Citius Oncology. NoveCite, was inactive until October 2020. On August 12, 2024, Citius Oncology, previously a wholly-owned subsidiary, became a 92.3% majority-owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operations of NoveCite and Citius Oncology are included in the consolidated results. The portion of equity that is not attributable to the Company, is presented as a non-controlling interest within stockholder’s equity. Unless excluded by shareholder agreements, the portion of net loss attributable to non-controlling interests is included in the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All share amounts and per share data reflect a 1-for-25 reverse stock split which went effective on November 25, 2024, subsequent to year-end which is more fully descripted in Note 13.</p>
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28201375	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29060212	usd
CY2024Q3	ctxr	Working Capital WorkingCapital	21600000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development, goodwill, stock-based compensation and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</p>
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	0	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	154611	usd
CY2024	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	2700000	usd
CY2023	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	7734895	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6134895	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2133862	usd
CY2024Q3	ctxr	Prepaid Manufacturing Costs PrepaidManufacturingCosts	6134895	usd
CY2024Q3	ctxr	In Process Research And Development Includes The Value Of Lmb InProcessResearchAndDevelopmentIncludesTheValueOfLMB	19400000	usd
CY2024	ctxr	Amortized Straight Line Basis Over Period AmortizedStraightLineBasisOverPeriod	P8Y
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements.</p>
CY2023Q1	ctxr	Annual Maintenance Fee AnnualMaintenanceFee	75000	usd
CY2022Q1	ctxr	Annual Maintenance Fee AnnualMaintenanceFee	60000	usd
CY2024	ctxr	Milestone Fees MilestoneFees	33700000	usd
CY2024Q2	ctxr	Direct Offering Common Shares DirectOfferingCommonShares	857143	shares
CY2024Q2	ctxr	Purchase Price PurchasePrice	17.5
CY2024Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	15000002	usd
CY2024	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	18168	shares
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	252140	usd
CY2024	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	247396	usd
CY2024	us-gaap	Professional Fees ProfessionalFees	84735	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	532207	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.75
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M28D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	56203	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	166400	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.5
CY2024	ctxr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P9Y14D
CY2024	ctxr	Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted	0	usd
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2125	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.38
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	39068	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	40398	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	68.5
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	656084	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.41
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	347618	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	44.4
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M7D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	24.44
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	13.38
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P36M
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11839678	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6616705	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2945337	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2945337	shares
CY2024Q3	us-gaap	Dividends Dividends	350241	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	238823	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	238824	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	25809	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	4771	usd
CY2024	us-gaap	Lease Cost LeaseCost	264632	usd
CY2023	us-gaap	Lease Cost LeaseCost	243595	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	253883	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21460	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	275343	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12478	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	262865	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246247	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	454426	usd
CY2024Q3	ctxr	Operating Lease Assets OperatingLeaseAssets	246247	usd
CY2023Q3	ctxr	Operating Lease Assets OperatingLeaseAssets	454426	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	241547	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	218380	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21318	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262865	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	262865	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	481245	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	30644	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	47176	usd
CY2024	us-gaap	Payments For Fees PaymentsForFees	250000	usd
CY2024	us-gaap	Production And Distribution Costs ProductionAndDistributionCosts	17300000	usd
CY2025Q3	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	11900000	usd
CY2026Q3	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	5400000	usd
CY2024Q3	ctxr	Agreements Amount AgreementsAmount	4500000	usd
CY2025Q3	us-gaap	Other Commitment OtherCommitment	2900000	usd
CY2026Q3	us-gaap	Other Commitment OtherCommitment	1600000	usd
CY2024	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	2387842	usd
CY2023	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	3585689	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	576000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	576000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.063	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.063	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.055	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.037	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.233	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.254	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.015	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0178	pure
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39888000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34980000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3310000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2191000	usd
CY2024Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5762000	usd
CY2023Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3644000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4861000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4100000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53821000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44915000	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	6713800	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	6137800	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6713800	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6137800	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6713800	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6137800	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8906000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4984000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	155000000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	35000000	usd
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	120000000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4250000	usd
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.25
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-25
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.001
CY2024Q3	us-gaap	Share Price SharePrice	1
CY2023Q3	us-gaap	Inventory Gross InventoryGross		usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2023Q3	ctxr	License Payable LicensePayable		usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2024	ctxr	Minority Interest From Merger MinorityInterestFromMerger		usd
CY2024	ctxr	Net Loss Attributable To Noncontrolling Interest NetLossAttributableToNoncontrollingInterest		usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023	ctxr	License Payment LicensePayment		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	ctxr	Ip Ramp D Milestones Included In License Payable IPRampDMilestonesIncludedInLicensePayable		usd
CY2023	ctxr	Prepaid Manufacturing Transferred To Inventory PrepaidManufacturingTransferredToInventory		usd
CY2024Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001506251

Files In Submission

Name	View Source	Status
0001213900-24-113149-index-headers.html	Edgar Link	pending
0001213900-24-113149-index.html	Edgar Link	pending
0001213900-24-113149.txt	Edgar Link	pending
0001213900-24-113149-xbrl.zip	Edgar Link	pending
ctxr-20240930.xsd	Edgar Link	pending
ea0225656-10k_citius.htm	Edgar Link	pending
ea022565601ex19-1_citius.htm	Edgar Link	pending
ea022565601ex23-1_citius.htm	Edgar Link	pending
ea022565601ex31-1_citius.htm	Edgar Link	pending
ea022565601ex31-2_citius.htm	Edgar Link	pending
ea022565601ex32-1_citius.htm	Edgar Link	pending
ea022565601ex4-22_citius.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
ctxr-20240930_def.xml	Edgar Link	unprocessable
ctxr-20240930_lab.xml	Edgar Link	unprocessable
ctxr-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0225656-10k_citius_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctxr-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

2024 Q4 Form 10-K Financial Statement

#000121390024113149 Filed on December 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR Citius Pharmaceuticals, Inc. Stock $ctxr

2024 Q4 Form 10-K Financial Statement

#000121390024113149 Filed on December 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr